Key facts
- This page summarizes Richard S. Casten's Form 4 filing for Baudax Bio, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 Aug 2021, 18:42.
Richard S. Casten - 20 Aug 2021 Form 4 Insider Report for Baudax Bio, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 20 Aug 2021
- Net transaction value
- +$25,500
- SEC form
- 4
- Accepted by SEC
- 23 Aug 2021, 18:42:26 UTC
- Prior SEC filing
- 17 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard S. Casten
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard S. Casten filed Form 4 for Baudax Bio, Inc. on 23 Aug 2021.
Change
- Previous filing in this sequence was filed on 17 May 2021.
- Current net transaction value: +$25,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BXRX
transaction
Common Stock
Purchase
- Transaction value
- $25,500
- Shares
- +50,000
- Change %
- +33%
- Price
- $0.5100
- Shares after
- 200,000
- Date
- 20 Aug 2021
- Ownership
- Direct
* marks a reported price that did not pass the local price check.